The software can also identify intracerebral hemorrhages. Credit: Raman Oza / Pixabay.

Digital health company Methinks has secured CE mark for its Methinks Stroke Suite medical imaging software.

The Methinks Stroke Suite is claimed to be the first CE-marked medical device that can help locate large vessel occlusions (LVO), both hyperdense and not, from non-contrast computed tomographies (NCCT) images.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The radiological computer-aided triage and notification system uses artificial intelligence (AI) algorithms to detect suspected LVO on NCCT images as well as computed tomography angiography (CTA).

The AI-based software also has the potential to identify intracerebral haemorrhages (ICH) on NCCT images.

According to the company, the software works in parallel with clinical workflows and leverages CT scans that are available in all hospitals.

See Also:

Furthermore, the ability of the device has been validated in 3,800 cases from three different stroke reference hospitals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Methinks CEO Pau Rodriguez said: “We are delighted with the CE mark approval for our medical imaging software, Methinks Stroke Suite, which paves the way to enhance stroke patient outcomes by decreasing detection time and reducing disabilities.

“Our software has the potential to be used in every hospital globally to improve the standard of care of patients.

“The approval comes at a pivotal time ahead of US FDA submission and launching a series A financing to accelerate our growth plans by leveraging and personalising imaging software.”    

Based in Barcelona, Spain, Methinks is involved in the development of AI-based medical imaging software to identify cerebral artery occlusions and haemorrhages.